Model-Independent Platform Accurately Predicts Drugs’ Stable States to Guide Reformulation for Enhanced Bioavailability
BEND, OR– Agere Pharmaceuticals, Inc., a leading oral bioavailability contract research and manufacturing organization (CRO/CMO), announced today that it has enhanced the Agere drug delivery platform to include prediction technology that identifies best-fit polymer candidates for drug solubilization and formulation. Agere’s polymer-selection system for drugs integrates directed experiments with rigorous computations to predict and measure key functions of the drug and candidate polymers. These functions are analyzed to accurately predict and rank order empirically-observed behaviors of the drug-polymer compound.
Polymer selection is one of the critical first steps in enhancing the bioavailability of compounds. Identifying the most probable candidates for solubilization allows subsequent formulation design and development efforts to focus on exploration and optimization of likely successful drug-polymer combinations. Agere is unconstrained in the excipients it considers, as the company has no IP ownership of polymers, and therefore clients benefit from a far reaching and agnostic approach.
“Our new technology further extends the Agere platform to leverage formulation design automation and analysis using fundamental science and proprietary techniques,” commented Marshall Crew, president and CEO of Agere. “Our goal was to put a system in place that enables us to quickly consider an expanding spectrum of likely excipients in order to achieve the best bioavailability options for our clients.”
Pharmaceutical companies facing solubility challenges with active pharmaceutical ingredients (APIs) depend on Agere’s expertise and scientific approach to enhance the bioavailability of their drugs. Agere services span formulation design and development into clinical trial drug manufacturing. All services are offered “`a la carte”, allowing companies the flexibility to engage with Agere at any stage in their process. Agere provides all services on a fee-for-service basis, in which Agere assumes no intellectual property (IP) ownership over work done on behalf of the company’s clients.
Agere is a leading CRO/CMO focused on improving the oral bioavailability of insoluble APIs. The company supports clients from formulation design and development through cGMP manufacturing for Phase I, Phase II and Phase IIb clinical trials. All services are delivered on a fee-for-service basis, and every project the company undertakes is customized to serve each individual client’s requirements. Agere is located in Bend, OR. For more information, visit www.agerepharma.com.
©2013 Agere Pharmaceuticals, Inc. Agere Pharmaceuticals is a trademark of Agere Pharmaceuticals, Inc.
Agere Pharmaceuticals, Inc.
Casey Jones, +1-702-994-0605
jones@agerepharma.com
Total Page Views: 900
